First author (publication year) | Study design | No of patients | Group | Age (year) | Male (%) | Genotype (%) | SVR (%) | Fibrosis-4 index | HCV-RNA (log IU/mL) | Baseline LDL (mg/dL) | Exclusion criteria |
---|---|---|---|---|---|---|---|---|---|---|---|
Özdoğan (2020) | NA | 93 | SOF/LDV | 64.1 (12.8)a | 32.3 | 1: 96.7 2: 2.5 4: 0.8 | SVR12: 98.4 | NA | 3.5 (10.0)a | 81.7 (28.4)a | HIV or HBV infection, HCC, liver transplant, patients taking lipid-lowering agents |
28 | PTVr/OBV + DSV | 64.1 (14.3)a | 85.7 | 3.0 (7.5)a | 89.7 (26.2)a | ||||||
Inoue (2018) | NA | 85 | SOF/LDV | 64.4 (13.3)a | 43.5 | 1b: 100 | SVR24: 97.8 | 3.4 (2.4)a | NA | 102.8 (25.5)a | NA |
46 | SOF/RBV | 62.0 (15.3)a | 32.6 | 2: 100 | SVR24: 98.8 | 3.5 (2.8)a | 103.2 (28.0)a | ||||
85 | ASV/DCV | 68.3 (10.5)a | 38.8 | 1b: 100 | SVR24: 81.2 | 4.3 (2.9)a | 98.3 (29.0)a | ||||
Endo (2017) | Retrospective cohort study | 132 | SOF/LDV | 66.7 (13.1)a | 37.1 | 1b: 100 | SVR12: 100 | 4.7 (4.0)a | 5.9 (0.87)a | 89.2 (28.5)a | HIV infection, HCC, decompensated cirrhosis |
121 | ASV/DCV | 68.4 (11.8)a | 48.8 | 1b: 100 | SVR12: 100 | 4.9 (3.3)a | 5.9 (0.78)a | 82.8 (27.2)a | |||
Kan (2017) | NA | 55 | SOF/LDV | 70.0 (20–86)c | 56.4 | 1a/1b: 9/91 | SVR12: 100 | 47.3% (≥ 3.25) | 6.1 (2.5–7.2)c | 77.0 (34–139)c | Decompensated cirrhosis, patients taking lipid-lowering agents |
40 | PTVr/OBV | 67.0 (46–85)c | 72.5 | 1b: 100 | SVR12: 100 | 55.0% (≥ 3.25) | 6.2 (3.9–7.3)c | 75.5 (38–134)c | |||
Notsumata (2017) | NA | 140 | SOF/LDV | 71.0 (26–87)c | 40.2 | NA | SVR12: 99.1 | NA | NA | 90.2 (22.9)a | NA |
100 | SOF/RBV | SVR12: 98.7 | 98.1 (25.3)a | ||||||||
173 | ASV/DCV | SVR12: 93.8 | 88.7 (30.0)a | ||||||||
50 | PTVr/OBV | SVR12: 96.3 | 101.3 (24.4)a | ||||||||
Hashimoto (2016) | Retrospective cohort study | 76 | SOF/LDV | 69.0 (63.0- 75.0)b | 40.8 | 1: 100 | NA | 67.1% (≥ 3.25) | 6.0 (5.6–6.4)b | 87.5 (68.6–105.8) b | Patients taking lipid-lowering agents |
24 | ASV/DCV | 76.0 (69.0- 80.0)b | 33.3 | 1: 100 | NA | 79.2% (≥ 3.25) | 6.1 (5.4–6.4)b | 80.2 (65.3–94.6)b |